New combo therapy targets hard-to-treat sarcoma

NCT ID NCT06528769

Recruiting now Disease control Sponsor: Gabriel Tinoco Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs—ATRA and cemiplimab—can shrink or control advanced leiomyosarcoma that has stopped responding to standard treatments. About 16 adults with metastatic or locally advanced, inoperable leiomyosarcoma will receive ATRA pills for 3 days before each cemiplimab infusion, then cemiplimab alone until the disease worsens or side effects become too severe. The main goal is to see how many patients' tumors shrink significantly.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

leiomyosarcoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEIOMYOSARCOMA SARCOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

Contact Email: •••••@•••••

Contact